EMA Deals with Manufacturing Deficiencies for Cancer Medicine - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Deals with Manufacturing Deficiencies for Cancer Medicine


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has recommended that the anticancer medicine DepoCyte be recalled from EU countries following the discovery of manufacturing deficiencies at Pacira Pharmaceuticals’ San Diego site. The deficiencies identified relate to adequate sterility assurance in the manufacturing process of DepoCyte. Production and batch release of the medicine are currently on hold, and new batches will only be manufactured once the deficiencies have been resolved and GMP compliancy confirmed by a reinspection.

According to a press release from EMA, there has been no evidence of any microbial contamination of DepoCyte on the market. The recall is being implemented as a precautionary measure in countries where suitable alternatives are available. For countries without therapeutic alternatives, DepoCyte will remain on the market, but with specific recommendations for monitoring patient safety and any signs of infection.

The inspection was conducted jointly by regulators from France and the UK at the DepoCyte manufacturing site in San Diego in July 2012. The EMA’s Committee for Medicinal Products for Human Use (CHMP) believes that the lack of sterility assurance poses a theoretical risk of sterility failure. Current data, however, have not suggested that there has been any Negative impact on the finished product.

DepoCyte is a prolonged release liposomal suspension for injection containing cytarabine for the intrathecal treatment of lymphomatous meningitis. The medicine was authorized in the EU in July 2001.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here